| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | 28,6 k € | +110.0% | -284,9 k € | |
| EBITDA | -341,9 k € | -19.7% | -285,7 k € | |
| Operating profit | -709,7 k € | -118.5% | -324,8 k € | |
| Profit/loss | -612,5 k € | -76.2% | -347,5 k € | |
| Equity | 4,3 M € | +20.6% | 3,6 M € | |
| Total assets | 5,8 M € | +33.0% | 4,3 M € | |
| Cash | 1,2 M € | -61.4% | 3,2 M € | |
| Debts | 1,4 M € | +94.8% | 722,1 k € | |
| Staff | 3,1 | — | ||
Source: Belgian Official Gazette
Private limited company · Mont-Saint-Guibert · incorporated on 20/12/2023 · 3,1 ETP
Private limited company loss-making in the latest fiscal year. Cash position declining (-61.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
BiocSol is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Mont-Saint-Guibert. It employs on average 3,1 ETP workers (FTE).